Key takeaways
Psychedelics are gaining mainstream acceptance: Growing research and regulatory momentum are pushing psychedelic therapies closer to becoming approved treatments for mental health conditions like depression, anxiety, and PTSD.
Different business models offer unique opportunities: Companies like MindMed focus on drug development, Numinus Wellness provides therapy services, and Compass Pathways leads in clinical trials—offering investors a range of ways to gain exposure to the sector.
High risk, high reward industry: While the potential for groundbreaking treatments is massive, regulatory hurdles, clinical trial outcomes, and funding challenges make psychedelic stocks highly speculative investments, and should not be invested in without exceptionally high tolerance for risk.
3 stocks I like better than the ones on this list.In This Article
- COMPASS Pathways Plc (CMPS)
- Mind Medicine Mindmed Inc (DFTX)
- Psyence Biomedical LTD (PBM)
⚠ Volatility Notice: This article contains micro-cap and/or small-cap stocks (under $1B market cap). These companies tend to have lower trading volume and can experience significantly higher price volatility than large-cap stocks. Please exercise additional caution and conduct thorough due diligence before investing.
COMPASS Pathways Plc (NASDAQ: CMPS)
$11.16
Overall Grade5.3 / 10
COMPASS Pathways Plc (NASDAQ: CMPS) is a mental healthcare company dedicated to accelerating patient access to evidence-based psychedelic therapies. The company is primarily focused on developing COMP360, a proprietary formulation of psilocybin, for treatment-resistant depression (TRD) and other mental health conditions...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-1.8
P/B2.3
P/S-
P/FCF-4.7
FCF Yield-21.4%
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)+2.3%
Revenue 5yr-
EPS 5yr+12.0%
FCF 5yr+14.4%
Fundamentals
Market Cap$746M
Dividend Yield-
Operating Margin-
ROE-130.6%
Interest Coverage-
Competitive Edge
- COMP360 psilocybin therapy targets treatment-resistant depression, a condition affecting ~100M people globally with no adequate existing treatments. FDA Breakthrough Therapy designation accelerates the regulatory path and signals agency engagement.
- COMPASS owns a proprietary psilocybin formulation plus a scalable therapy delivery model, creating a dual moat of drug IP and care infrastructure that pure-play drug developers lack.
- The psychedelic medicine regulatory environment is shifting rapidly in COMPASS's favor. Oregon and Australia have already approved psilocybin frameworks, creating precedent that de-risks the FDA pathway.
- First-mover advantage in building therapist training networks and treatment center partnerships creates real switching costs. Competitors entering later must build this infrastructure from scratch.
- Mental health is experiencing a secular funding tailwind from both public and private payers, driven by post-pandemic demand and recognition that existing SSRIs and SNRIs have limited efficacy in resistant populations.
By the Numbers
- Net cash position of $413M ($4.52 cash per share) against a $13.06 stock price means 35% of the market cap is backed by cash. For a pre-revenue biotech, this cash runway is the single most important survival metric.
- EPS losses are narrowing: 3Y CAGR improvement of 14.1% and 5Y CAGR of 12.0%, with YoY improvement of 2.3%. The burn rate trajectory is bending in the right direction even as Phase 3 trials scale up.
- FCF-to-net-income conversion of 89% signals high earnings quality with minimal accrual distortions. For a clinical-stage company, this tight alignment means reported losses accurately reflect real cash consumption.
- Current ratio of 3.32 and quick ratio of 3.03 with zero capex indicate the company can sustain current burn for roughly 2+ years without needing to raise capital, reducing near-term dilution risk.
- Momentum grade of 9.4/10 is the strongest signal in the dataset. Combined with a Valuation grade of 6.7/10, the market is repricing CMPS upward but hasn't yet reached expensive territory.
Risk Factors
- Shares outstanding grew 10.3% YoY while buyback yield is negative 21.4%, meaning the company is aggressively issuing equity. Every dollar of future value is being split across a rapidly expanding share base.
- ROIC of negative 413% and ROE of negative 131% reflect a company destroying capital at scale. These are expected for clinical-stage biotech, but the magnitude underscores how much future revenue must materialize to justify the current $1.6B market cap.
- SBC of $12.6M against zero revenue means stock comp is a pure dilution cost with no revenue base to absorb it. This represents roughly 7.5% of the trailing cash burn, quietly eroding shareholder value.
- FCF worsened 7.6% YoY even as EPS improved slightly, suggesting operating cash burn is accelerating as trials progress. The divergence between improving EPS and deteriorating FCF deserves monitoring.
- Profitability grade of 0.3/10 is essentially zero, the lowest score in the entire grade profile. While expected for pre-revenue biotech, it confirms this is a pure binary bet on clinical and regulatory outcomes.
Mind Medicine Mindmed Inc (NASDAQ: DFTX)
$23.74
Overall Grade0.0 / 10
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and other novel therapies to address brain health disorders...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-
P/B-
P/S-
P/FCF-
FCF Yield-
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-
Revenue 5yr-
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$0M
Dividend Yield-
Operating Margin-
ROE-
Interest Coverage-
Competitive Edge
- MM120 (lysergide d-tartrate) for generalized anxiety disorder has a differentiated mechanism of action versus SSRIs and benzodiazepines. If approved, it would be the first psychedelic-derived therapy for GAD, a market with 6.8M+ U.S. patients and high unmet need.
- FDA Breakthrough Therapy Designation for MM120 in GAD significantly de-risks the regulatory path, enabling rolling review and more frequent FDA interaction, which historically correlates with higher approval probability versus standard review.
- MindMed's focus on session-free or short-session psychedelic models addresses the biggest commercial bottleneck for competitors like MAPS/Lykos (MDMA therapy requires 3 eight-hour sessions), making MindMed's approach far more scalable in real-world clinical settings.
- The company's IP strategy around specific formulations and dosing regimens of known psychedelic compounds creates a defensible position that pure-play psilocybin competitors like Compass Pathways lack, given the composition-of-matter angle on the d-tartrate salt form.
- Growing institutional acceptance of psychedelic medicine, evidenced by state-level legalization in Oregon and Colorado, creates a regulatory tailwind that reduces political risk for FDA approval and commercial launch.
By the Numbers
- With $2.06B market cap and a P/B of 6.2x, the implied tangible book value around $332M suggests MindMed still holds substantial cash reserves from prior capital raises, critical for a pre-revenue biotech where cash runway is the single most important metric.
- The EV/EBITDA of -10.2x, combined with the market cap, implies enterprise value is meaningfully below market cap, confirming a net cash position that extends operational runway without immediate need for dilutive financing.
- At $20.18 per share, the stock has clearly re-rated higher from its historical lows, suggesting the market is pricing in meaningful probability of clinical success, particularly around the MM120 program for generalized anxiety disorder.
Risk Factors
- TTM stock-based compensation of $20.1M is enormous relative to a company with zero revenue. SBC alone likely represents 6%+ of market cap annually, and the negative buyback yield of -0.23% confirms share count is growing, not shrinking. Shareholders are being steadily diluted.
- Negative FCF yield of -6.4% and negative earnings yield of -10.3% mean the company is burning roughly $131M and $212M respectively on a trailing basis. At that burn rate, even a healthy cash position has a finite and calculable expiration date.
- Shareholder yield is deeply negative at -1.2%, combining dilution from SBC, no buybacks, and net debt issuance (debt paydown yield of -0.97%). Every capital return metric is working against existing shareholders simultaneously.
- P/B of 6.2x for a clinical-stage biotech with no approved products means the market is pricing in over $1.7B of intangible pipeline value above book. If the lead program stumbles in Phase 3, that premium evaporates quickly.
- Binary clinical risk is extreme. MindMed's entire valuation hinges on MM120 Phase 3 readouts. A single failed trial could wipe 50-70% of market cap overnight, as seen with Lykos Therapeutics' FDA rejection of MDMA therapy in 2024.
Psyence Biomedical LTD (NASDAQ: PBM)
$3.37
Overall Grade0.0 / 10
Psyence Biomedical Ltd. is a Canadian-based biotechnology company dedicated to advancing the field of psychedelic-assisted therapy...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-
P/B-
P/S-
P/FCF-
FCF Yield-
Growth & Outlook
Rev Growth (YoY)-
EPS Growth (YoY)-
Revenue 5yr-
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$0M
Dividend Yield-
Operating Margin-
ROE-
Interest Coverage-
Competitive Edge
- Psilocybin-assisted therapy for palliative care targets a genuine unmet need with growing clinical evidence. FDA granted Breakthrough Therapy designations to competitors like COMPASS Pathways, validating the therapeutic class and potentially smoothing PBM's own regulatory path.
- Natural psilocybin differentiation versus synthetic competitors (COMPASS Pathways' COMP360) could matter for regulatory positioning and patient/clinician preference, particularly as the psychedelic therapy field matures and product differentiation becomes important.
- Canadian domicile provides a more permissive regulatory environment for psychedelic research compared to the U.S., reducing early-stage R&D friction. Health Canada's Special Access Programme already allows psilocybin use in certain cases, giving PBM potential near-term clinical access.
- Palliative care focus is a strategically smart entry point. It faces less regulatory resistance than broader mental health indications because the patient population has limited treatment options and terminal prognoses, which lowers the risk-benefit threshold for approval.
By the Numbers
- EV/EBITDA of 1.09x is extraordinarily low, suggesting the market assigns near-zero value to the enterprise beyond its current cash and liabilities. For a biotech with any pipeline optionality, this implies the market prices in terminal failure, which creates asymmetric upside if any program advances.
- P/B of 0.22x means the stock trades at roughly 22 cents on the dollar of book value. Even accounting for intangible-heavy biotech balance sheets, trading this far below book suggests the market discounts the company's assets to near-liquidation value.
- Market cap of ~$2.6M against a stock price of $4.15 implies an extremely small share count (roughly 630K shares), which limits the float and could create sharp upside moves on any positive catalyst or institutional interest.
Risk Factors
- Negative FCF yield of -140.6% means the company is burning cash at a rate that exceeds its entire market cap annually. At $2.6M market cap, this cash burn rate gives the company a dangerously short runway without additional financing, which will almost certainly be dilutive.
- Buyback yield of -3.9% confirms active share dilution, not repurchases. Combined with $26K in TTM stock-based compensation (small in absolute terms but material relative to a $2.6M market cap, roughly 1% of equity value annually), shareholders are being diluted while the company generates no revenue.
- Earnings yield of -241.5% translates to losses roughly 2.4x the entire market cap on a trailing basis. For a pre-revenue biotech, cash runway is the critical metric, and losses of this magnitude relative to market cap signal existential financing risk.
- The P/E of -0.004x is essentially meaningless in isolation, but inverting it confirms the company lost approximately $630M relative to its price, which is clearly a data artifact. The key takeaway is that losses are so large relative to equity value that traditional valuation frameworks break down entirely.
- COMPASS Pathways (CMPS, ~$500M+ market cap) and Usona Institute are years ahead in psilocybin clinical development. PBM's $2.6M market cap means it cannot compete on R&D spending, clinical trial scale, or regulatory engagement with these better-funded rivals.
